METHODS OF TREATING CANCER, HAVING HEMIZYGOUS LOSS OF TP53 Russian patent published in 2020 - IPC C12N15/113 A61K31/7088 C12Q1/68 

FIELD: biotechnology.

SUBSTANCE: methods are provided for treating a patient with cancer, which demonstrates: (i) hemizygous loss of TP53 gene; (ii) hemizygous loss of the POLR2A gene; and/or (iii) reduced expression level of POLR2A gene product relative to reference (i.e. control) level of expression. Methods include administering a therapeutically effective amount of a POLR2A (amatoxin, alpha-amanitine or alpha-amanitine conjugated with a target-interacting molecule, such as an EpCAM antibody) to a patient, which has or has presence of: (i) hemizygous loss of TP53 gene; (ii) hemizygous loss of the POLR2A gene; and/or (iii) low level of expression of the product of the POLR2A gene relative to the reference (i.e. control) level.

EFFECT: methods are suggested for treating cancer, having hemizygous loss TP53.

31 cl, 76 dwg, 2 tbl, 4 ex